Posts tagged retinal disease
Roth starts IRIDEX at buy

Roth Capital Partners initiated coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and $20 price target. The stock closed at $13.22 on Dec. 20.

Read More
Ocular, Regeneron in wet AMD collaboration

Ocular Therapeutix (NASDAQ:OCUL) has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (NASDAQ:REGN) to develop a sustained release formulation of the vascular endothelial growth factor (VEGF) trap, aflibercept, for the treatment of wet age-related macular degeneration (AMD) and other retinal diseases.

Regeneron’s aflibercept has been approved by the FDA for certain indications under the brand name, EYLEA.

Read More
QLT and Aegerion Pharma to merge

QLT (NASDAQ:QLTI; TSX:QLT) and Aegerion Pharmaceuticals (NASDAQ:AEGR) have entered into a definitive merger agreement, with the resulting company to be renamed, Novelion Therapeutics.

Under the accord, each outstanding share of Aegerion common stock will be exchanged for 1.0256 shares of QLT common stock.

Read More